Sarcomatrix Therapeutics Corp.
10:45 AM - 11:00 AM (EDT), Thursday, June 8, 2023 ・ Session Room 104A
Sarcomatrix is a pre-clinical biotech developing first-in-class drugs to treat muscle wasting diseases, starting with the most severe forms, muscular dystrophies. Our potent α7β1 integrin enhancers promote muscle regeneration in all muscle types by stimulating satellite cells activation and increase myofiber fusion. Our path to age related (sarcopenia) and drug related (cachexia) muscle wasting is through muscular dystrophy.
.png)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Nevada
Company HQ Country:
United States
Year Founded:
2022
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
S-969, α7β1 integrin enhancer, oral small molecule
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Three (3)
Speaker
